Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
143
resultados
Última actualización
16/11/2025 [06:55:00]
Resultados 125 a 143 de 143
Resumen de: EP4620393A1
This application discloses a blood glucose monitoring method, a graphical interface, and a related apparatus. In the method, a wearable device collects a PPG signal of a user used to reflect blood glucose of the user within a time period, removes a low-quality PPG signal collected when the user is affected by an external factor, and determines, based on a reserved PPG signal, a quantity of occurrences of a blood glucose abnormality and/or a blood glucose risk of the user within the time period. It can be learned that, when data used to reflect the blood glucose of the user is collected, the user may be affected by the external factor, and the device may remove the PPG signal collected when the user is affected by the external factor. In this way, a status of the user does not need to be considered in a blood glucose monitoring process, thereby achieving an effect of unperceived blood glucose monitoring.
Resumen de: EP4620384A2
User interfaces for glucose insight presentation are leveraged. A glucose monitoring application is configured to process glucose measurements to determine one or more glucose insights, e.g., about a user's glucose. The glucose measurements, for example, may be obtained from a glucose monitoring device that collects glucose measurements of the user at predetermined intervals, e.g., every five minutes. The glucose monitoring application configures a user interface, based on configuration data, to present one or more visual elements representative of the one or more glucose insights. For example, the glucose monitoring application may configure the user interface to include a visual element in the form of a color field which represents whether the user's current glucose measurement (e.g., the most recent glucose measurement obtained from the glucose monitoring device) is below, within, or above a glucose range.
Resumen de: EP4621804A2
Methods, devices and system for determining fasting glucose level information and post-prandial glucose level information for diagnosing pre-diabetic and diabetic conditions based on monitored glucose measurements are provided.
Resumen de: LU600638B1
The present invention discloses a construction system for a cardiovascular disease risk prediction model for patients with type 2 diabetes, comprising a bottom base, a mounting slot, a prediction system, a data collection and preprocessing module, a feature selection and extraction module, a model construction module, amodel evaluation and validation module, a user interaction module, a speaker, and a display. The bottom base is provided with a mounting slot, within the mounting slot the prediction system is arranged. The present invention is designed as an integrated and comprehensive construction system for a cardiovascular disease risk prediction model for patients with type 2 diabetes. Based on the results of multifactorial Logistic regression analysis, a highly accurate risk prediction model is constructed. Furthermore, statistical methods are employed to validate the predictive performance of the model, providing a novel tool for identifying high-risk individuals for cardiovascular disease among patients with type 2 diabetes. Additionally, the present invention not only considers traditional risk factors but also incorporates biochemical indicators such as serum albumin, serum uric acid, and parathyroid hormone.
Resumen de: AU2025223826A1
A sensor applicator assembly for a continuous glucose monitoring system is provided. The sensor applicator assembly is assembled as a single unitary product in which a sensor module measuring a blood glucose level is preinstalled in an applicator, such that the sensor module is ejected by an operation of the applicator to be attached to a human body. The applicator includes a main container and a plunger body fixedly coupled to a first position within the main container. The plunger body is configured to be decoupled from the first position and to be moved to a second position in an injecting direction. The sensor module is coupled to one end portion of the plunger body to be moved integrally with the plunger body as the plunger body being moved toward the second position. An adhesive layer is attached to a lower surface of the sensor module to attach the sensor module to the human body, and is configured to be moved together with the sensor module as the plunger body being moved toward the second position. A sensor applicator assembly for a continuous glucose monitoring system is provided. The sensor applicator assembly is assembled as a single unitary product in which a sensor module measuring a blood glucose level is preinstalled in an applicator, such that the sensor module is ejected by an operation of the applicator to be attached to a human body. The applicator includes a main container and a plunger body fixedly coupled to a first position within the main container. T
Resumen de: AU2025223845A1
Multiple enzymes may be present in one or more active areas of an electrochemical analyte sensor for detecting one or more different analytes. In particular, an analyte sensor may comprise a sensor tail configured for insertion into a tissue and one or more working electrodes having a glucose-responsive active area and an ethanol- responsive active area to detect glucose and ethanol in vivo. Multiple enzymes may be present in one or more active areas of an electrochemical analyte sensor for detecting one or more different analytes. In particular, an analyte sensor may comprise a sensor tail configured for insertion into a tissue and one or more working electrodes having a glucose-responsive active area and an ethanol- responsive active area to detect glucose and ethanol in vivo. ug u l t i p l e e n z y m e s m a y b e p r e s e n t i n o n e o r m o r e a c t i v e a r e a s o f a n e l e c t r o c h e m i c a l u g a n a l y t e s e n s o r f o r d e t e c t i n g o n e o r m o r e d i f f e r e n t a n a l y t e s n p a r t i c u l a r , a n a n a l y t e s e n s o r m a y c o m p r i s e a s e n s o r t a i l c o n f i g u r e d f o r i n s e r t i o n i n t o a t i s s u e a n d o n e o r m o r e w o r k i n g e l e c t r o d e s h a v i n g a g l u c o s e - r e s p o n s i v e a c t i v e a r e a a n d a n e t h a n o l - r e s p o n s i v e a c t i v e a r e a t o d e t e c t g l u c o s e a n d e t h a n o l i n v i v o
Resumen de: WO2025193785A1
A method of determining a dosage regimen for a glucose disorder includes receiving existing dosage information for a patient at a computing device and receiving, by the computing device, glucose data from a patient using a continuous glucose monitor. Next, the method includes determining a glycemic risk for a time period based on the glucose data, and modifying an existing basal insulin dosage when the glycemic risk indicates an elevated risk of a high glucose level in at least one time period and when the glycemic risk does not indicate an elevated risk of low glucose, and when the existing basal insulin dosage is below a predetermined maximum. Next, the method includes initiating a prandial insulin dose when the glycemic risk indicates an elevated risk of a high glucose level and when the existing basal insulin dosage is at a predetermined maximum.
Resumen de: WO2025194017A1
Systems and methods of optimizing glucose medication dosages are based on modeling a patient's glucose lowering response using historical glucose data. The model is actively updated to account for changes in the patient's medication treatments and physiological conditions based on real-time or near real-time glucose measurements from the patient. The system can analyze various dosages of insulin based on the patient's current therapy and the model to determine an optimized dosage. Also disclosed is a system and method for retrieving a patient's current medication therapies from medical records using an automated system. Also disclosed are methods of implementing remotely-updatable limitations for medication optimization algorithms.
Resumen de: US2025288224A1
Systems and methods of optimizing glucose medication dosages are based on modeling a patient's glucose lowering response using historical glucose data. The model is actively updated to account for changes in the patient's medication treatments and physiological conditions based on real-time or near real-time glucose measurements from the patient. The system can analyze various dosages of insulin based on the patient's current therapy and the model to determine an optimized dosage. Also disclosed is a system and method for retrieving a patient's current medication therapies from medical records using an automated system. Also disclosed are methods of implementing remotely-updatable limitations for medication optimization algorithms.
Resumen de: US2025288225A1
A non-invasive continuous blood glucose concentration (BGC) measurement method and apparatus based on optical coherence tomography angiography (OCTA) are provided. The method includes: performing continuous OCT scanning and imaging on a target tissue region; extracting, based on a depth attenuation characteristic of an OCT signal, a three-dimensional optical scattering coefficient of the target tissue region; generating a three-dimensional microvascular distribution of the target tissue region; accurately distinguishing a blood optical scattering coefficient (BOC) from a tissue optical scattering coefficient (TOC) based on the three-dimensional scattering coefficient and the three-dimensional microvascular distribution; and measuring reference BGCs at two time points through an electrochemical method; and combining the reference BGCs with the BOC and the TOC respectively, thereby achieving continuous measurement of a BGC and an interstitial fluid glucose concentration (IGC). The method and apparatus are based on OCTA to achieve accurate BGC measurement while simultaneously enabling IGC measurement.
Resumen de: WO2025189236A1
Some embodiments relate to devices and methods for determining a measure of glucose in a first substance. An example device may comprise: a light source configured to emit near-infrared light at a first wavelength at a first quantity of the first substance, the first substance comprising a second substance and glucose; a detector, configured to: detect light from the first substance; and provide a signal indicative of an intensity of the detected light; and a controller, configured to: receive the signal from the detector; determine a first measure indicative of the intensity of the detected light from the first substance; determine a measure of glucose in the first substance as a difference between the first measure and a second measure, wherein the second measure is indicative of the intensity of detected light from a second quantity of the second substance when subjected to near-infrared light at the first wavelength; and provide an output based on the determined measure of glucose.
Resumen de: US2025288228A1
An analyte sensor configured to compensate for insulin interference includes: a working electrode, including an analyte sensing molecule disposed on the working electrode configured to generate a signal when exposed to an analyte; a processor; and a memory. The memory includes instructions which, when executed by the processor, cause the sensor to: obtain an indication from the pump that the bolus is delivered; in response to the delivery of the bolus, determine at least one of a first electrochemical impedance spectroscopy (EIS) parameter value or a first conductivity value in response to exposure of the working electrode to the analyte; and determine a presence of one or more interferents based on at least one of the first EIS parameter value or the first conductivity value.
Resumen de: US2025288226A1
Methods, devices, and systems are provided. A method includes receiving sensor data from the glucose sensor, the sensor data being associated with a time window, determining a rate of change distribution of the sensor data, determining a first slope that corresponds to a line of the rate of change distribution, comparing a first slope with a first reference slope, generating, based on comparing the first slope with the first reference slope, an output; and, transmitting the output to a display or a transmitter. Numerous additional features are disclosed.
Resumen de: WO2025193719A1
A system for continuous glucose measurement and spinal cord stimulation provides at least two implantable non-stimulation electrodes configured to continuously monitor at least one physiological parameter on a lead that also includes a plurality of implantable stimulation electrodes. The electrodes are electrically connected to an implantable pulse generator that communicates stimulation instructions and glucose measurement data.
Resumen de: US2024306955A1
The present disclosure relates to a continuous blood sugar measuring device, and provides a continuous blood sugar measuring device which is capable of minimizing additional work of a user in order to attach a body attachment unit, by manufacturing the body attachment unit to be assembled inside an applicator so that the body attachment unit can be attached to the body simply by operating the applicator and, particularly: communicating with an external terminal by providing a wireless communication chip in the body attachment unit so that simple and convenient use is possible and maintenance can easily be performed without the additional work of connecting a separate transmitter; initiating operation by a manipulation of the user, after attaching the body attachment unit to the body, so that an operation initiation time can be adjusted to a suitable time according to the need of the user; and initiating operation in a stabilized state to enable a more accurate measurement of blood sugar.
Resumen de: EP4616800A1
An analyte sensor configured to compensate for insulin interference includes: a working electrode, including an analyte sensing molecule disposed on the working electrode configured to generate a signal when exposed to an analyte; a processor; and a memory. The memory includes instructions which, when executed by the processor, cause the sensor to: obtain an indication from the pump that the bolus is delivered; in response to the delivery of the bolus, determine at least one of a first electrochemical impedance spectroscopy (EIS) parameter value or a first conductivity value in response to exposure of the working electrode to the analyte; and determine a presence of one or more interferents based on at least one of the first EIS parameter value or the first conductivity value.
Resumen de: EP4616799A1
Provided is a sensor applicator assembly for a blood glucose monitoring, comprising an applicator, and a body attachment unit disposed inside the applicator and comprising a housing including an upper frame and a lower frame. The lower frame comprises a recess portion formed throughout an entire section along a perimeter direction.
Nº publicación: EP4616802A2 17/09/2025
Solicitante:
I SENS INC [KR]
I-SENS, INC
Resumen de: EP4616802A2
The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.
BOPI
Sede Electrónica
